Marksans Pharma profit and loss

Latest FY26

Revenue: ₹2,951cr+1,025.1% on FY25
EBITDA: ₹601cr+1,036.5% on FY25
Net profit: ₹420cr+997.9% on FY25
EPS: ₹9.22+9.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	3,172	2,951	262	2,177	1,852	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	102	82.5	7.0	50.4	59.3
	3,274	3,033	269	2,228	1,911
	987	959	75.3	668	613
	421	454	57.4	444	315
	−49.6	−136	−18.4	−73.9	−6.4
	437	421	35.0	294	239
	25.1	24.1	1.2	11.2	9.1
	100	98.6	8.3	74.3	51.9
	662	652	60.0	387	352
	2,584	2,473	219	1,804	1,574
	714	601	52.9	459	339
	613	502	44.5	384	287
Profit
	691	561	50.4	424	338
	691	561	50.4	424	338
	185	153	12.9	113	71.2
	−16.0	−12.5	−0.7	−4.7	1.1
	169	140	12.1	109	72.3
	521	420	38.3	315	265
	521	420	38.3	315	265
	127	176	4.8	28.6	52.2
	648	596	43.1	343	318
	517	418	38.3	343	266
	4.5	2.2	0.0	0.9	−1.0
Per share
	₹11.41	₹9.22	₹8.40	₹6.92	₹6.41
	₹11.41	₹9.22	₹8.40	₹6.92	₹6.41
Other comprehensive income — detail
	127	176	4.8	—	—
	1.8	1.4	−0.0	0.4	−0.8
	0.5	0.4	−0.0	—	—
	—	—	—	0.1	−0.2
	125	175	4.8	28.3	52.8
	639	589	—	343	318
	8.5	7.1	—	0.9	−0.8
Per share — as-filed variants
	₹11.41	₹9.22	₹8.40	₹6.92	₹6.41
	₹11.41	₹9.22	₹8.40	₹6.92	₹6.41
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,813	1,674	148	1,139	931
	57.2%	56.7%	56.4%	52.3%	50.3%
Adjusted (ex-exceptional items) — derived
	691	561	50.4	424	338
	521	420	38.3	315	265
	₹11.41	₹9.22	₹8.40	₹6.92	₹6.41

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersGRANULES METROPOLIS PARKHOSPS JLHL HCG RUBICON SHILPAMED SPARCMcap ₹14,290 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,852.1	2,177.4	262.3	2,950.9	3,171.7
Other Income	59.3	50.4	7.0	82.5	102.3
Total Income	1,911.5	2,227.8	269.3	3,033.5	3,274.0
Expenses
+ Cost of Materials Consumed	613.0	667.7	75.3	959.2	987.2
+ Purchases of Stock-in-Trade	314.8	444.3	57.4	454.5	421.4
+ Changes in Inventories	-6.4	-73.9	-18.4	-136.4	-49.6
+ Employee Benefit Expense	239.4	293.6	35.0	420.9	436.8
+ Finance Costs	9.1	11.2	1.2	24.1	25.1
+ Depreciation & Amortisation	51.9	74.3	8.3	98.6	100.4
+ Other Expenses	352.1	387.1	60.0	651.9	662.3
Total Expenses	1,573.8	1,804.3	218.9	2,472.9	2,583.5
EBITDA	339.3	458.6	52.9	600.8	713.7
EBIT	287.5	384.3	44.5	502.1	613.3
Profit
PBT before Exceptional Items	337.7	423.5	50.4	560.6	690.5
Pretax Income	337.7	423.5	50.4	560.6	690.5
+ Current Tax	71.2	113.3	12.9	153.0	185.3
+ Deferred Tax	1.1	-4.7	-0.7	-12.5	-16.0
Tax Expense	72.3	108.6	12.1	140.5	169.3
Net Income	265.3	314.9	38.3	420.1	521.3
+ Net Income — Continuing Ops	265.3	314.9	38.3	420.1	521.3
+ Other Comprehensive Income	52.2	28.6	4.8	176.1	126.6
Total Comprehensive Income	317.5	343.5	43.1	596.2	647.9
Net Income to Common	266.3	342.6	38.3	417.9	516.7
Minority Interest	-1.0	0.9	0.0	2.2	4.5
Per Share
Basic EPS	6.41	6.92	8.40	9.22	11.41
Diluted EPS	6.41	6.92	8.40	9.22	11.41
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	4.8	176.1	126.6
+ Items NOT to be Reclassified to P&L	-0.8	0.4	-0.0	1.4	1.8
+ Tax on Items NOT to be Reclassified	—	—	-0.0	0.4	0.5
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	0.1	—	—	—
+ Items to be Reclassified to P&L	52.8	28.3	4.8	175.1	125.3
Comprehensive Income — Owners of Parent	318.3	342.6	—	589.2	639.4
Comprehensive Income — Non-controlling Interests	-0.8	0.9	—	7.1	8.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.41	6.92	8.40	9.22	11.41
Diluted EPS — Continuing Operations	6.41	6.92	8.40	9.22	11.41
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	930.8	1,139.3	147.9	1,673.7	1,812.8
Gross Margin %	50.25	52.32	56.39	56.72	57.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	337.7	423.5	50.4	560.6	690.5
Net Income Adj (tax-effected)	265.3	314.9	38.3	420.1	521.3
EPS Adj	6.41	6.92	8.40	9.22	11.41
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	45.3	45.3	4.5	45.3	45.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.